National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
No longer in the register. This agreement was last published in the January 2023 edition and was not in the February 2023 edition. NHS Digital merged into NHS England on 1 February 2023, and agreements within the merged organisation moved to a separate internal register, so this agreement most likely moved rather than ended. This page shows what the register last said, and it is not counted in this site's figures.
NHS England (Quarry House) · Agency/Public Body
Listed under NHS England.
- Reference
- DARS-NIC-192305-X3T0Y
- Latest version
- v15.4
- Term of latest version
- 18 November 2021 to 31 May 2024
- Start date
- Before 1 December 2019
- Data controller
- Sole Data Controller
- Commercial purposes
- No
- Sublicensing
- Yes
- Files released to date
- 0
Why the data was released
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
• monitor cancer waiting times targets
• plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62-day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, Cancer Alliances and the Department of Health and Social Care to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
A. Record level de-identified patient data (anonymised, without a record ID or pseudonym)
B. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level pseudonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset has been accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. Use aggregate and record level data to produce monthly, quarterly and annual Official Statistics. Risk of disclosure are managed in line with official statistics protocols.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Three Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 18th June 2022. As such, a temporary sub-licensing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Processing activities
This application is for online permissions to access the record level NCWTMDS via the NHS Digital system and iView tool.
The system can only be accessed by approved users via an N3 connection.
1. NHS England's national analytics team in Performance Analysis Team require access to aggregate and record data so that this can be analysed to produce Official Statistics on cancer waiting times. These statistics are published on a monthly, quarterly and annual basis and report the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or breast symptoms and, for patients with cancer, on the numbers who started treatment within 31 and 62 days for each organisation.
2. NHS England’s national analytics team in Performance Analysis Team and the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) within the Cancer Programme Team require access to aggregate reports, including small numbers, and record level data to undertake more detailed analysis and reporting. This is to support activities outlined under point 2 in section 5a above. Record level data are required, for example, to calculate length of the whole pathway and phases at the pathway at various points along the distributions e.g. medians, 75th, 85th and 95th percentile and complete other statistical analysis that cannot be derived from pre-aggregated data alone.
Aggregate reports including small numbers:
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by Cancer Alliances, as they routinely monitor performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches, counts must accurately reflect the true percentage without suppression of small numbers.
The attached diagram and tables identify the actors involved including description of the flows of data, user roles and organisations (NHS England, NHS Digital, Cancer Alliances), contracting structures and enforcement.
3. NHS England’s regional analytics teams in Performance Analysis Team and Directors of Commissioning Operations analytics teams require access to aggregate and record level data so that these can be analysed to produce regional reports on cancer waiting times on a monthly and quarterly basis, as well as more detailed analysis as required to assess performance and identify regional outliers.
4. NHS England's national and regional analytics teams require access to ad-hoc reports for analysing CWT policy and providing evidence for policy implementation, involves processing record level pseudonymised data with aggregate outputs, suppressed where appropriate. Aggregate outputs to be shared with NHS England teams to inform policy decisions. Users wishing to access the system will require authorisation from the NHS England Senior Information Risk Officer (SIRO) or Information Asset Owner (IAO) before access will be granted by NHS Digital. NHS England is responsible for ensuring that only individuals with a legitimate need to access the data are approved as users. NHS England users are granted the permission to locally download record level extracts from the system and such downloads must be stored and processed securely on NHS England servers. No patient identifiable data is provided, and records should not be linked to any other source.
Data will only be accessed by individuals employed by NHS England who have authorisation from the SIRO or IAO to access the data for the purposes described, all of whom are personnel working under appropriate supervision on behalf of NHS England. Following completion of the analysis any record level data will be securely destroyed. Users are not permitted to upload data into the system. The data will not be used for commercial use. The data will not be linked with any record level data and there will be no requirement nor attempt to re-identify individuals from the data.
All organisations party to this agreement must comply with the Data Sharing Framework Contract requirements, including those regarding the use (and purposes of that use) by "Personnel" (as defined within the Data Sharing Framework Contract i.e.: employees, agents and contractors of the Data Recipient who may have access to that data).
ONWARD SHARING
Data may be shared with a Cancer Alliance only where:
- The individual Cancer Alliance data sharing agreement references this agreement - 192305.
Expected output
Expected Output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
- Analysis to underpin delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
- Comparative Cancer Waiting Times performance at tumour group and site for Cancer Alliances, Trusts and CCGs
- Analysis of Cancer Waiting Times performance by treatment and tumour group and site to inform policy and operational discussions.
- Identifying variation which may impact cancer patients' outcomes or patient experience in order to support national policy discussions
Expected measurable benefits
1, 2 and 3. Enabling analysis of the Cancer Waiting Times data on a system wide basis will provide insight to focus service improvements on most effective areas to improve performance. In particular you would expect that access to the data be essential to delivery of the Cancer Waiting Times standards:-
• 2 week wait urgent GP referral – 93%
• 2 week wait breast symptomatic – 93%
• 31 day 1st treatment - 96%
• 31 day subsequent surgery – 94%
• 31 day subsequent drugs – 98%
• 31 day subsequent radiotherapy – 94%
• 62 day (GP) referral to 1st treatment – 85%
• 62 day (screening ) referral to 1st treatment – 90%
• 62 day upgrade to 1st treatment – locally agreed standard
• 28 day referral to diagnosis – between 70% and 85% (as this standard is being introduced from April 2020, the threshold will be subject to review and amendment on a yearly basis)
Comparison of performance by tumour type aggregate reports will provide insight into how adjustments and general operation of the CWT dataset and guidance rules apply in the system, and whether policy decisions need to be made to amend the dataset and rules to reflect changing performance or volumes within CWT. The overall aim of this type of additional analysis would be to support improvements to cancer patients' survival and experience. The NHS Long Term Plan set out a number of ambitions to be met by 2028 including increasing the proportions of patients staged 1 or 2 from around half now to three-quarters. Achieving this means that from 2028, 55,000 more people each year will survive their cancer for at least five year after diagnosis. For these, improvements to ensure optimal diagnostic and treatment pathways and nationally agreed processes are key, and require NHS England policy teams to be able to analyse the Cancer Waiting Times dataset to identify improvements.
Cancer Alliances are key to driving the change needed across England to deliver the NHS Long Term Plan commitments around cancer. They bring together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway. They provide the opportunity for a different way of working to improve and transform Cancer Services. They are responsible for directing funding to transform service and care across whole pathways , reducing variation in the availability of good care and treatment for all to improve survival, early diagnosis , patient experience and long-term quality of life. Success will be seen through improvements in indicators including the 62 day wait standard. The CWT data will enable these benefits to be realised.
4. The benefits of having the breast screening cohort data will be to understand the full impact of the screening invitation error incident, monitor and plan for potential impact on secondary care providers, and to enable the organisation to take steps to ensure robust procedures are in place to prevent future re-occurrence.
Benefits reported so far
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
Datasets on the latest version
Legal basis for provision: Health and Social Care Act 2012 - s261 - 'Other dissemination of information'
| Dataset | Type of data | Sensitivity | Frequency | Confidential data |
|---|---|---|---|---|
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS) | Anonymised - ICO Code Compliant | Sensitive | System Access | Does not include the flow of confidential data |
Files released
Files released counts only files released externally by DARS. Access granted in NHS England's own systems, such as its Secure Data Environment, is not included.
This agreement permits sublicensing: the applicant may pass data on to others. Anything passed on is not recorded in this register.
No files recorded as released under this agreement.
Version history
The register lists each renewal of this agreement as a separate row. This site has 8 versions — earlier versions existed before this site's records begin.
DARS-NIC-192305-X3T0Y-v15.4 18 November 2021 to 31 May 2024
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v14.1
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2021-11-18 |
Objective for processing
[18 paragraphs unchanged]
Two
Three
Cancer Alliances do not yet have an active Data Sharing Agreement with
[42 words unchanged]
support to ensure that DSAs with NHS Digital are active from 18th
December 2021.
June 2022.
As such, a temporary sub-licensing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
[11 paragraphs unchanged]
Processing activities
[2 paragraphs unchanged]
1. NHS England's national analytics team in
Operational Information for Commissioning
Performance Analysis Team
require access to aggregate and record data so that this can be
[53 words unchanged]
numbers who started treatment within 31 and 62 days for each organisation.
2. NHS England’s national analytics team in
Operational Information for Commissioning
Performance Analysis Team
and the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) within the
[68 words unchanged]
complete other statistical analysis that cannot be derived from pre-aggregated data alone.
[4 paragraphs unchanged]
3. NHS England’s regional analytics teams in
Operational Information for Commissioning
Performance Analysis Team
and Directors of Commissioning Operations analytics teams require access to aggregate and
[26 words unchanged]
more detailed analysis as required to assess performance and identify regional outliers.
[6 paragraphs unchanged]
Unchanged: Expected output, Expected measurable benefits, Benefits reported.
DARS-NIC-192305-X3T0Y-v14.1 1 June 2021 to 31 May 2024
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v13.2
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2021-06-01 | |
| End date | 2024-05-31 | |
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS): sensitivity | Sensitive |
Objective for processing
[18 paragraphs unchanged]
Four
Two
Cancer Alliances do not yet have an active Data Sharing Agreement with
[42 words unchanged]
support to ensure that DSAs with NHS Digital are active from 18th
June
December
2021. As such, a temporary sub-licensing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
[11 paragraphs unchanged]
Unchanged: Processing activities, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
• monitor cancer waiting times targets
• plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62-day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, Cancer Alliances and the Department of Health and Social Care to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
A. Record level de-identified patient data (anonymised, without a record ID or pseudonym)
B. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level pseudonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset has been accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. Use aggregate and record level data to produce monthly, quarterly and annual Official Statistics. Risk of disclosure are managed in line with official statistics protocols.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Two Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 18th December 2021. As such, a temporary sub-licensing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Expected output
Expected Output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
- Analysis to underpin delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
- Comparative Cancer Waiting Times performance at tumour group and site for Cancer Alliances, Trusts and CCGs
- Analysis of Cancer Waiting Times performance by treatment and tumour group and site to inform policy and operational discussions.
- Identifying variation which may impact cancer patients' outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v13.2 1 December 2020 to 18 June 2021
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v12.2
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
Objective for processing
[18 paragraphs unchanged]
Four Cancer Alliances do not yet have an active Data Sharing Agreement
[42 words unchanged]
provide support to ensure that DSAs with NHS Digital are active from
1st April
18th June
2021. As such, a temporary
sub-licencing
sub-licensing
measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
[11 paragraphs unchanged]
Unchanged: Processing activities, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
• monitor cancer waiting times targets
• plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62-day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, Cancer Alliances and the Department of Health and Social Care to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
A. Record level de-identified patient data (anonymised, without a record ID or pseudonym)
B. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level pseudonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset has been accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. Use aggregate and record level data to produce monthly, quarterly and annual Official Statistics. Risk of disclosure are managed in line with official statistics protocols.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Four Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 18th June 2021. As such, a temporary sub-licensing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Expected output
Expected Output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
- Analysis to underpin delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
- Comparative Cancer Waiting Times performance at tumour group and site for Cancer Alliances, Trusts and CCGs
- Analysis of Cancer Waiting Times performance by treatment and tumour group and site to inform policy and operational discussions.
- Identifying variation which may impact cancer patients' outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v12.2 1 December 2020 to 18 June 2021
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v11.2
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2020-12-01 | |
| National Cancer Waiting Times Monitoring DataSet (NCWTMDS): legal basis | Health and Social Care Act 2012 - s261 - 'Other dissemination of information' |
Objective for processing
[18 paragraphs unchanged]
Four Cancer Alliances do not yet have an active Data Sharing Agreement
[42 words unchanged]
provide support to ensure that DSAs with NHS Digital are active from
1 December 2020.
1st April 2021.
As such, a temporary sub-licencing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
[11 paragraphs unchanged]
Unchanged: Processing activities, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
• monitor cancer waiting times targets
• plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62-day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, Cancer Alliances and the Department of Health and Social Care to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
A. Record level de-identified patient data (anonymised, without a record ID or pseudonym)
B. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level pseudonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset has been accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. Use aggregate and record level data to produce monthly, quarterly and annual Official Statistics. Risk of disclosure are managed in line with official statistics protocols.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Four Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 1st April 2021. As such, a temporary sub-licencing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Expected output
Expected Output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
- Analysis to underpin delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
- Comparative Cancer Waiting Times performance at tumour group and site for Cancer Alliances, Trusts and CCGs
- Analysis of Cancer Waiting Times performance by treatment and tumour group and site to inform policy and operational discussions.
- Identifying variation which may impact cancer patients' outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v11.2 19 June 2020 to 18 June 2021
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v10.6
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2020-06-19 | |
| End date | 2021-06-18 |
Objective for processing
[1 paragraph unchanged]
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
•monitor cancer waiting times targets
can be used to:
•plan service improvements
• monitor cancer waiting times targets
• plan service improvements
[1 paragraph unchanged]
The NCWTMDS provides the data used to publish the official cancer
62 day
62-day
treatment target which is one of the key national statistics used to
[8 words unchanged]
the cancer waiting times data can also be queried by NHS organisations,
cancer networks
Cancer Alliances
and the Department of Health
and Social Care
to provide reports and feedback on the progress towards meeting these targets.
[1 paragraph unchanged]
1.
A.
Record level
de-identified
patient data (anonymised, without a record ID or pseudonym)
2.
B.
Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing
[22 words unchanged]
access to that level of data, and can only access record level
anonymised
pseudonymised
data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset
will be
has been
accessed via the new Cancer Waiting Times System and NHS Digital iView tool
https://www.digital.nhs.uk/tools-for-accessing-data/iView-and-iViewPlus
https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
[1 paragraph unchanged]
1.
The national analytics team will use
Use aggregate and
record level data to produce
monthly
monthly, quarterly
and
quarterly
annual
Official Statistics.
Risk of disclosure are managed in line with official statistics protocols.
2. Regional teams and the Commissioning Operations Directorate will use aggregate data for the purpose of performance management.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics team, with only aggregate data to be shared with other NHS England teams.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
This agreement supersedes any previous data sharing agreements in place to access this dataset via Open Exeter.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Four Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 1 December 2020. As such, a temporary sub-licencing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Processing activities
This application is for online permissions to access the record level NCWTMDS via the NHS Digital system and iView tool.
The system can only be accessed by approved users via an N3 connection.
NHS England's national analytics team require access to record level data so that this can be analysed to produce Official Statistics on cancer waiting times. These statistics are published on a monthly and quarterly basis and report the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or breast symptoms and, for patients with cancer, on the numbers who started treatment within 31 and 62 days for each organisation. Record level data is required to calculate medians and complete other statistical analysis that cannot be derived from pre-aggregated data alone. NHS England’s Regional analytics teams and Directors of Commissioning Operations analytics teams require access to aggregate record level data so that this can be analysed to produce regional reports on cancer waiting times on a monthly and quarterly basis, which allows them to assess performance and identify regional outliers.
The system can only be accessed by approved users via an N3 connection.
Users wishing to access the system will require authorisation from the NHS England SIRO or IAO before access will be granted by NHS Digital; this is managed via a Data Users Certificate (DUC) form that is completed by each organisation accessing the system. NHS England is responsible for ensuring that only individuals with a legitimate need to access the data are approved as users. NHS England users are granted the permission to locally download record level extracts from the system and such downloads must be stored and processed securely on NHS England servers. No patient identifiable data is provided, and records should not be linked to any other source.
1. NHS England's national analytics team in Operational Information for Commissioning require access to aggregate and record data so that this can be analysed to produce Official Statistics on cancer waiting times. These statistics are published on a monthly, quarterly and annual basis and report the number of people who attended outpatient appointments within two weeks of an urgent referral by their GP for suspected cancer or breast symptoms and, for patients with cancer, on the numbers who started treatment within 31 and 62 days for each organisation.
Data will only be accessed by individuals within NHS England who have authorisation from the SIRO or IAO to access the data for the purposes described, all of whom are personnel working under appropriate supervision on behalf of NHS England. Following completion of the analysis any record level data will be securely destroyed. Users are not permitted to upload data into the system. The data will not be used for commercial use. The data will not be linked with any record level data and there will be no requirement nor attempt to re-identify individuals from the data.
2. NHS England’s national analytics team in Operational Information for Commissioning and the Cancer Alliance Data, Evidence and Analysis Service (CADEAS) within the Cancer Programme Team require access to aggregate reports, including small numbers, and record level data to undertake more detailed analysis and reporting. This is to support activities outlined under point 2 in section 5a above. Record level data are required, for example, to calculate length of the whole pathway and phases at the pathway at various points along the distributions e.g. medians, 75th, 85th and 95th percentile and complete other statistical analysis that cannot be derived from pre-aggregated data alone.
The raw data will not be made available to any third parties except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics.
Aggregate reports including small numbers:
Aggregate data is available in the form of reports at Provider (Trust) and Clinical Commissioning Group (CCG) level.
Small numbers may be included in the aggregate data reports and are essential for analyses carried out by Cancer Alliances, as they routinely monitor performance and standards using the CWT system, particularly in relation to breaches of the 62 day wait target. Due to the large number of potential Trust/CCG combinations, breach counts could result in small numbers as in some cases there are less than 6 breaches in a whole year. Given that financial penalties are linked to target breaches, counts must accurately reflect the true percentage without suppression of small numbers.
The attached diagram and tables identify the actors involved including description of the flows of data, user roles and organisations (NHS England, NHS Digital, Cancer Alliances), contracting structures and enforcement.
3. NHS England’s regional analytics teams in Operational Information for Commissioning and Directors of Commissioning Operations analytics teams require access to aggregate and record level data so that these can be analysed to produce regional reports on cancer waiting times on a monthly and quarterly basis, as well as more detailed analysis as required to assess performance and identify regional outliers.
4. NHS England's national and regional analytics teams require access to ad-hoc reports for analysing CWT policy and providing evidence for policy implementation, involves processing record level pseudonymised data with aggregate outputs, suppressed where appropriate. Aggregate outputs to be shared with NHS England teams to inform policy decisions. Users wishing to access the system will require authorisation from the NHS England Senior Information Risk Officer (SIRO) or Information Asset Owner (IAO) before access will be granted by NHS Digital. NHS England is responsible for ensuring that only individuals with a legitimate need to access the data are approved as users. NHS England users are granted the permission to locally download record level extracts from the system and such downloads must be stored and processed securely on NHS England servers. No patient identifiable data is provided, and records should not be linked to any other source.
Data will only be accessed by individuals employed by NHS England who have authorisation from the SIRO or IAO to access the data for the purposes described, all of whom are personnel working under appropriate supervision on behalf of NHS England. Following completion of the analysis any record level data will be securely destroyed. Users are not permitted to upload data into the system. The data will not be used for commercial use. The data will not be linked with any record level data and there will be no requirement nor attempt to re-identify individuals from the data.
[1 paragraph unchanged]
ONWARD SHARING
Data may be shared with a Cancer Alliance only where:
- The individual Cancer Alliance data sharing agreement references this agreement - 192305.
Expected output
Expected Output
[2 paragraphs unchanged]
All outputs will contain only data that is compliant with the relevant disclosure control rules including suppression and rounding.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
Additional outputs consist of:
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
•
-
Analysis to
support
underpin
delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
•
-
Comparative Cancer Waiting Times performance at tumour group
and site
for Cancer Alliances, Trusts and CCGs
•
-
Analysis of Cancer Waiting Times performance by treatment
and tumour group and site
to inform
policy and operational
discussions.
•
-
Identifying variation which may impact cancer
patient’s
patients'
outcomes or patient experience in order to support national policy discussions
Expected measurable benefits
1, 2 and 3. Enabling analysis of the Cancer Waiting Times data on a system wide [23 words unchanged] the data be essential to delivery of the Cancer Waiting Times standards:- [10 paragraphs unchanged] Comparison of performance by tumour type aggregate reports will provide insight into how adjustments and general operation of the CWT dataset and guidance rules apply in the system, and whether policy decisions need to be made to amend the dataset and rules to reflect changing performance or volumes within CWT. The overall aim of this type of additional analysis would be to support improvements to cancer patients' survival and experience. The NHS Long Term Plan set out a number of ambitions to be met by 2028 including increasing the proportions of patients staged 1 or 2 from around half now to three-quarters. Achieving this means that from 2028, 55,000 more people each year will survive their cancer for at least five year after diagnosis. For these, improvements to ensure optimal diagnostic and treatment pathways and nationally agreed processes are key, and require NHS England policy teams to be able to analyse the Cancer Waiting Times dataset to identify improvements. Cancer Alliances are key to driving the change needed across England to deliver the NHS Long Term Plan commitments around cancer. They bring together local clinical and managerial leaders from providers and commissioners who represent the whole Cancer pathway. They provide the opportunity for a different way of working to improve and transform Cancer Services. They are responsible for directing funding to transform service and care across whole pathways , reducing variation in the availability of good care and treatment for all to improve survival, early diagnosis , patient experience and long-term quality of life. Success will be seen through improvements in indicators including the 62 day wait standard. The CWT data will enable these benefits to be realised. 4. The benefits of having the breast screening cohort data will be to understand the full impact of the screening invitation error incident, monitor and plan for potential impact on secondary care providers, and to enable the organisation to take steps to ensure robust procedures are in place to prevent future re-occurrence.
Changed only in punctuation, spacing or capitalisation: Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data
can be used to:
• monitor cancer waiting times targets
• plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62-day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, Cancer Alliances and the Department of Health and Social Care to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
A. Record level de-identified patient data (anonymised, without a record ID or pseudonym)
B. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level pseudonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset has been accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iViewand-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. Use aggregate and record level data to produce monthly, quarterly and annual Official Statistics. Risk of disclosure are managed in line with official statistics protocols.
2. Use aggregate and record level data to undertake more detailed analysis and reporting to (i) monitor performance against the NHS constitutional standards in relation to cancer services. Monitoring and investigation of the data allows NHS England to meet its responsibilities in holding the healthcare system to account for delivering care to patients as set out in the constitution; (ii) support policy development, for example, evidence to inform changes to the CWT dataset and guidance, ensuring that NHS England policy decisions are based on a strong evidence base; and (iii) support operational delivery and service improvement, for example, identifying priority areas to focus on and making changes to pathways.
This agreement will permit NHS England to share aggregate Cancer Waiting Times (CWT) data containing small numbers with the data controller and processor(s) named in each applicable Cancer Alliance data sharing agreement. This aggregate unsuppressed data can only be shared while both this agreement and the data sharing agreement for the relevant Cancer Alliance remains active, and where the Cancer Alliance agreement contains appropriate wording to cover this data sharing. If NHS England are notified that a Cancer Alliance's data sharing agreement has expired or otherwise ended then NHS England must ensure any flow of aggregate unsuppressed data to that Cancer Alliance is halted.
The outputs shared with Cancer Alliances are aggregate data reports at various geographical levels which are essential to Cancer Alliances to enable analyses to be carried out and to understand local performance, both of individual providers and of the system in general. This analysis has to be undertaken at the most appropriate level for action to be taken and performance to be benchmarked; thus allowing patients to experience improvements to the system. For Cancer, this is specific tumour site level which is only possible with unsuppressed data. Introducing small number suppression would result in these reports having no practical use and leave Cancer Alliances without a way in which they can understand variation in performance between providers and improve the system. Cancer Alliances have already been provided with access to unsuppressed data in their data sharing agreements held directly between NHS Digital and each lead organisation responsible for employing the Cancer Alliance users of the system.
Currently, the CWT national system does not provide full coverage of the data requested by Cancer Alliances in their data sharing agreements with NHS Digital. Only a limited amount of aggregate reports and record level data is available directly in the CWT system. NHS England are working with the development team to rectify this issue but based on competing policy priorities and finite financial resources it is likely that this development will not be fully realised. Therefore, NHS England’s Cancer Alliance, Data, Evidence and Analysis Service (CADEAS) will be required to provide Alliances with aggregate data for monthly and quarterly performance management and monitoring use within the NHS. This may include small numbers. This temporary arrangement includes only those Cancer Alliances that do not yet have the required data via the Cancer Waiting Times Dataset.
Four Cancer Alliances do not yet have an active Data Sharing Agreement with NHS Digital for the Cancer Waiting Times Dataset. These Cancer Alliances do not have the expertise and/or resources to complete a DSA application process during the current Covid-19 crisis and ‘restore’ period. NHS England will work with these Cancer Alliances to provide support to ensure that DSAs with NHS Digital are active from 1 December 2020. As such, a temporary sub-licencing measure is in place for this application to allow access to aggregate reports which may include small numbers as detailed.
In addition to the current restrictions in the CWT system, there is a longer term requirement for aggregate reports to be shared as detailed in section 5c. Specific Outputs Expected. These outputs are based on analysis conducted nationally and provide information for Cancer Alliances to enable further local analyses to be carried out and to understand and assure local performance. It would not be an efficient use of NHS resources for all Cancer Alliances to conduct the same level of data manipulation and presentation of outputs where initial data manipulation has already been conducted by the CADEAS team.
Risk of disclosure is minimised as the dataset does not include patient demographics that may allow users to identify an individual e.g. there are no age, ethnic categories or geographic breakdowns based on patient postcode.
Examples of this type of analysis include: -
a) Comparison of performance by tumour site for each standard (nationally, and at Sustainability and Transformation Partnership (STP), regional, Alliance, Clinical Commissioning Group (CCG) and provider levels)
b) National comparisons of trends in volumes of cases included for each standard
c) Treatment modality comparisons at tumour site level
d) Analysis of length of the whole pathway and phases of the pathway at various points along the distributions e.g. median, 75th, 85th and 95th percentiles.
3. Regional teams and Directors of Commissioning Operations teams will use aggregate data for the purpose of performance management and supporting the system to meet operational standards.
4. Access to ad-hoc sub-reports, specifically the breast screening cohort which is a sub-set of the data extracts required to produce monthly, quarterly and annual Official Statistics. The output will be used to inform policy decisions for the Director of the Cancer Programme team. The data is needed to conduct trend analysis on the specific cohort of patients who were identified as having missed a scheduled routine breast screening invitation. As part of the service response programme NHS England needs to be able to conduct analysis on those patients who, having been offered a screen, do go on to be diagnosed with a malignancy. This includes 62 day wait from referral from a cancer screening service to first treatment patients, as well as subsequent treatment activity and outcomes. Failure to understand the full scope and impact of the screening invitation errors could lead to reputational risk to the organisation and Public Health England at a later date.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party except in the form of aggregated outputs with small numbers suppressed in line with appropriate disclosure controls, such as Official Statistics; however aggregate report outputs containing small numbers may be shared with regional NHS England teams and Cancer Alliances as detailed above. Small numbers may be included in the aggregate data reports and are essential for analyses carried out, for example, to understand performance at provider level on a specific tumour site such as prostate and to benchmark performance against other similar providers. Suppressing small numbers would limit the utility of the reports and make performance and improvement discussions more challenging if both sides are not looking at the same numbers. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics teams employed by NHS England, with only aggregate data to be shared.
The GDPR lawful basis for NHS England to process this data is under Article 6(1)(e) 'task in the public interest', and Article 9(2)(h) ‘Health or social care purposes'.
Expected output
Expected Output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
1. Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
2, 3 and 4. Additional aggregate outputs provided directly to Cancer Alliances to aid them in their measurement of local system performance consist of:
- Analysis to underpin delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
- Comparative Cancer Waiting Times performance at tumour group and site for Cancer Alliances, Trusts and CCGs
- Analysis of Cancer Waiting Times performance by treatment and tumour group and site to inform policy and operational discussions.
- Identifying variation which may impact cancer patients' outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v10.6 1 June 2020 to 31 August 2020
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v9.5
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2020-06-01 | |
| End date | 2020-08-31 |
Unchanged: Objective for processing, Processing activities, Expected output, Expected measurable benefits, Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data can be used to:
•monitor cancer waiting times targets
•plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62 day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, cancer networks and the Department of Health to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
1. Record level patient data (anonymised, without a record ID or pseudonym)
2. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level anonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset will be accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iView-and-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. The national analytics team will use record level data to produce monthly and quarterly Official Statistics.
2. Regional teams and the Commissioning Operations Directorate will use aggregate data for the purpose of performance management.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics team, with only aggregate data to be shared with other NHS England teams.
This agreement supersedes any previous data sharing agreements in place to access this dataset via Open Exeter.
Expected output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
All outputs will contain only data that is compliant with the relevant disclosure control rules including suppression and rounding.
Additional outputs consist of:
• Analysis to support delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
• Comparative Cancer Waiting Times performance at tumour group for Cancer Alliances, Trusts and CCGs
• Analysis of Cancer Waiting Times performance by treatment to inform discussions.
• Identifying variation which may impact cancer patient’s outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v9.5 1 March 2020 to 31 May 2020
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
What changed from DARS-NIC-192305-X3T0Y-v8.4
Text removed is struck through; text added is underlined. Unchanged paragraphs are summarised rather than repeated.
| Field | Was | Became |
|---|---|---|
| Start date | 2020-03-01 | |
| End date | 2020-05-31 |
Objective for processing
[15 paragraphs unchanged]
This agreement
supercedes
supersedes
any previous data sharing agreements in place to access this dataset via Open Exeter.
Expected measurable benefits
[10 paragraphs unchanged]
• 28 day referral to diagnosis - TBC
• 28 day referral to diagnosis – between 70% and 85% (as this standard is being introduced from April 2020, the threshold will be subject to review and amendment on a yearly basis)
Unchanged: Processing activities, Expected output, Benefits reported.
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data can be used to:
•monitor cancer waiting times targets
•plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62 day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, cancer networks and the Department of Health to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
1. Record level patient data (anonymised, without a record ID or pseudonym)
2. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level anonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset will be accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iView-and-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. The national analytics team will use record level data to produce monthly and quarterly Official Statistics.
2. Regional teams and the Commissioning Operations Directorate will use aggregate data for the purpose of performance management.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics team, with only aggregate data to be shared with other NHS England teams.
This agreement supersedes any previous data sharing agreements in place to access this dataset via Open Exeter.
Expected output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
All outputs will contain only data that is compliant with the relevant disclosure control rules including suppression and rounding.
Additional outputs consist of:
• Analysis to support delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
• Comparative Cancer Waiting Times performance at tumour group for Cancer Alliances, Trusts and CCGs
• Analysis of Cancer Waiting Times performance by treatment to inform discussions.
• Identifying variation which may impact cancer patient’s outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
DARS-NIC-192305-X3T0Y-v8.4 1 December 2019 to 29 February 2020
- Title
- National Cancer Waiting Times Monitoring Data Set (NCWTMDS)
- Commercial
- No
- Sublicensing
- Yes
- Datasets
- 1
- Files released
- 0
Datasets: National Cancer Waiting Times Monitoring DataSet (NCWTMDS)
Objective for processing
The National Cancer Waiting Times Monitoring DataSet (NCWTMDS) is a national, patient level data collection by NHS Digital, under a Direction from NHS England (NHSE). The data are used for monitoring times taken to diagnose and treat patients with cancer and ensure these are in line with the expectations and rights of patients in the NHS Constitution.
The NHS Digital NCWTMDS online system allows NHS providers to record data derived from patient care activity. This data can be used to:
•monitor cancer waiting times targets
•plan service improvements
As a patient moves through the stages of their treatment pathway, data on referrals, treatments and diagnosis are derived from care records locally.
The NCWTMDS provides the data used to publish the official cancer 62 day treatment target which is one of the key national statistics used to monitor the performance of the NHS. After collection, the cancer waiting times data can also be queried by NHS organisations, cancer networks and the Department of Health to provide reports and feedback on the progress towards meeting these targets.
The NCWTMDS System will provide for NHS England online access to:
1. Record level patient data (anonymised, without a record ID or pseudonym)
2. Aggregate data (pre-defined tabulations, without disclosure control i.e. small number suppression)
Some organisations accessing the NCWTMDS system are permitted to download data containing the identifier NHS number, or containing a pseudonymised record identifier; however under this agreement NHS England will not be permitted to have access to that level of data, and can only access record level anonymised data (with no pseudonymised ID) and aggregate data.
NHS England previously had access to the dataset via Open Exeter, from Spring 2018 the dataset will be accessed via the new Cancer Waiting Times System and NHS Digital iView tool https://www.digital.nhs.uk/tools-for-accessing-data/iView-and-iViewPlus
NHS England requires access to the system for the following purpose(s):
1. The national analytics team will use record level data to produce monthly and quarterly Official Statistics.
2. Regional teams and the Commissioning Operations Directorate will use aggregate data for the purpose of performance management.
The data cannot be used for any other purpose than that stated above. The data will not be shared with any third party. Data will only ever be used for purposes relating to healthcare or the promotion of health in line with the requirements of the Health and Social Care Act 2012 as amended by the Care Act 2014. Any record level data extracted from the system will not be processed outside of the analytics team, with only aggregate data to be shared with other NHS England teams.
This agreement supercedes any previous data sharing agreements in place to access this dataset via Open Exeter.
Expected output
NHS England use NCWTMDS data on an ongoing basis for performance management purposes and for the production of national and official statistics. Statistical reports are published on a monthly and quarterly basis, and are available via the NHS England website: https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/
Monthly statistical reports are issued alongside a press release to increase impact and aid interpretation.
All outputs will contain only data that is compliant with the relevant disclosure control rules including suppression and rounding.
Additional outputs consist of:
• Analysis to support delivery of Cancer Waiting Times standard and identify variation, including discussions to improve patient pathways and target funding / new NHS England Cancer Programme projects
• Comparative Cancer Waiting Times performance at tumour group for Cancer Alliances, Trusts and CCGs
• Analysis of Cancer Waiting Times performance by treatment to inform discussions.
• Identifying variation which may impact cancer patient’s outcomes or patient experience in order to support national policy discussions
Benefits reported
• Publication of monthly and quarterly Official Statistics which allows health organisations to assess performance and benchmark, identifying outliers and policy developments required.
• Provision of transformation funding and National Cancer Programme projects, consisting of more than £250m, is provided to Cancer Alliances based on CWT Official Statistics performance as a benchmark for how ready the local system is to make changes and produce benefits from funding.
• National timed pathways which promote best practice for patient care and faster diagnosis of cancer and non-cancer patients have been developed based on performance of tumour groups identified in the Official Statistics.
• Local NHS England teams analyse performance and initiate improvement work locally, and identify outliers which have resulted in performance improvement and improved patient care / experience.
Register history
When this agreement appeared in, or was edited in, each monthly edition of the register. Built by comparing every edition this site holds, the earliest of which is July 2021.
-
July 2021 —
already listed in the earliest edition this site holds, so it may be older. 7 versions: DARS-NIC-192305-X3T0Y-v10.6, DARS-NIC-192305-X3T0Y-v11.2, DARS-NIC-192305-X3T0Y-v12.2, DARS-NIC-192305-X3T0Y-v13.2, DARS-NIC-192305-X3T0Y-v14.1, DARS-NIC-192305-X3T0Y-v8.4, DARS-NIC-192305-X3T0Y-v9.5
-
December 2021
1 version added: DARS-NIC-192305-X3T0Y-v15.4
-
December 2022
Register-wide edit DARS-NIC-192305-X3T0Y-v10.6, DARS-NIC-192305-X3T0Y-v11.2, DARS-NIC-192305-X3T0Y-v8.4, DARS-NIC-192305-X3T0Y-v9.5 — Datasets: legal basis: “
s261(1) and” taken out. Made to 639 agreements in this edition, so it is reported once, on the changes page, and not counted as an amendment of this agreement. -
February 2023
8 no longer listed: DARS-NIC-192305-X3T0Y-v10.6, DARS-NIC-192305-X3T0Y-v11.2, DARS-NIC-192305-X3T0Y-v12.2, DARS-NIC-192305-X3T0Y-v13.2, DARS-NIC-192305-X3T0Y-v14.1, DARS-NIC-192305-X3T0Y-v15.4, DARS-NIC-192305-X3T0Y-v8.4, DARS-NIC-192305-X3T0Y-v9.5(NHS Digital merged into NHS England that month, and agreements within the merged organisation moved to a separate internal register)
Cite this page
NHS England (2023) Data Uses Register, January 2023 edition, agreement DARS-NIC-192305-X3T0Y, “National Cancer Waiting Times Monitoring Data Set (NCWTMDS)”. Read via NHS Data Access Explorer (unofficial), https://healthdatauses.uk/agreements/dars-nic-192305-x3t0y/ (accessed [date]).
This address stays the same, but the page is rebuilt with each monthly edition, so the citation names the edition it shows. Every edition's data is kept in the facts store.
Source: datausesregister_september2026.xlsx, September 2026 edition of the NHS England Data Uses Register. Search that workbook for DARS-NIC-192305-X3T0Y to see the original rows.